In type 2 diabetes (T2D), treatment with subcutaneous (SC) injections of long-acting basal insulin analogs is recommended as the first step when initiating insulin therapy even though postprandial hyperglycemia occurs early in disease progression due to the loss of early-phase insulin secretion [2]. This evidence concerns the gene INS and type 2 diabetes mellitus.